GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Clal Biotechnology Industries CBI.TA · ILA

Health Care · Tel Aviv · 🇮🇱 Israel

Compare

22.80

-2.15%

Close of 9 Nov 2026, in ILA

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in ILS, from our data supplier.

FY2025

Revenue

ILS 835,000

FY2016FY2025

Net income

−ILS 13.3m

FY2016FY2025

Free cash flow

−ILS 4.1m

FY2016FY2025

Shareholders' equity

ILS 20.2m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueILS 835,000ILS 433,000ILS 104,000ILS 370,000ILS 224,000ILS 206,000ILS 113.3mILS 12.8mILS 43.5mILS 24.2m
Research and development———ILS 24.8mILS 33.1mILS 26.4mILS 10.0mILS 9.2mILS 32.6mILS 42.0m
Operating income−ILS 18.4m−ILS 6.6m−ILS 24.5mILS 46.6m−ILS 77.6mILS 40.2m−ILS 79.9m−ILS 91.0m−ILS 52.6m−ILS 178.3m
Net income−ILS 13.3m−ILS 62.5m−ILS 31.1m−ILS 61.7m−ILS 89.6mILS 109.0m−ILS 154.1m−ILS 44.9m−ILS 27.9m−ILS 213.8m
Diluted earnings per share-0.08-0.39-0.16-0.41-0.570.68-0.96-0.28-0.19-1.57

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsILS 41.8mILS 67.7mILS 158.4mILS 182.7mILS 444.9mILS 614.0mILS 617.0mILS 1.02bnILS 1.03bnILS 1.12bn
Cash and short-term investmentsILS 1.7mILS 5.0mILS 13.4mILS 12.9mILS 53.0mILS 186.5mILS 114.5mILS 103.8mILS 165.1mILS 171.0m
Total liabilitiesILS 19.0mILS 21.5mILS 37.0mILS 37.8mILS 106.5mILS 100.2mILS 119.1mILS 148.5mILS 226.1mILS 366.2m
DebtILS 17.8mILS 20.8mILS 35.8mILS 36.7mILS 11.7mILS 7.7mILS 19.9mILS 49.6mILS 71.9mILS 78.3m
Shareholders' equityILS 20.2mILS 36.6mILS 99.4mILS 126.0mILS 172.6mILS 306.3mILS 223.6mILS 398.9mILS 382.1mILS 363.1m
Shares outstanding166m158m192m151m158m161m161m159m149m136m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−ILS 4.1m−ILS 6.5m−ILS 8.5m−ILS 59.0m−ILS 41.3m−ILS 33.2mILS 27.0m−ILS 87.0m−ILS 91.4m−ILS 112.6m
Capital spending——−ILS 5,000−ILS 1.3m−ILS 1.6m−ILS 3.2m−ILS 2.8m−ILS 3.0m−ILS 4.7m−ILS 5.0m
Free cash flow−ILS 4.1m−ILS 6.5m−ILS 8.5m−ILS 60.3m−ILS 42.9m−ILS 36.4mILS 24.2m−ILS 89.9m−ILS 96.1m−ILS 117.6m
Dividends paid————−ILS 36.0m−ILS 36.0m−ILS 36.0m−ILS 36.0m——

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueILS 638,500ILS 638,500——————
Operating income−ILS 234,000−ILS 234,000−ILS 1.0m−ILS 1.0m−ILS 1.2m−ILS 1.2m−ILS 1.4m−ILS 1.4m
Net income−ILS 2.9m−ILS 2.9m−ILS 1.5m−ILS 1.5m−ILS 5.2m−ILS 5.2m−ILS 10.6m−ILS 10.6m
Diluted earnings per share-0.02-0.02-0.01-0.01-0.03-0.03-0.07-0.07
Cash from operations————−ILS 1.0m−ILS 1.0m−ILS 1.0m−ILS 1.0m
Total assetsILS 32.6mILS 32.6mILS 41.8mILS 41.8mILS 52.1mILS 52.1mILS 67.7mILS 67.7m
Cash and short-term investmentsILS 1.6mILS 1.6mILS 1.7mILS 1.7mILS 1.6mILS 1.6mILS 5.0mILS 5.0m
DebtILS 15.8mILS 15.8mILS 16.4mILS 16.4mILS 17.2mILS 17.2mILS 19.3mILS 19.3m
Shareholders' equityILS 12.8mILS 12.8mILS 20.2mILS 20.2mILS 23.9mILS 23.9mILS 36.6mILS 36.6m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue31.2%32.3%-28.9%
Operating income——-20.4%
Net income-40.0%—-19.6%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-1974.8%-173.1%-1862.3%-281.3%
Net margin-5975.9%-9676.6%-6865.7%-320.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-3.8-0.9-2.5-1.6-2.12.9-1.4-9.6-18.0-1.5
Price to sales61.2126.8—260.0——1.933.911.613.5

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 29 Mar 2021.

FY2021
Paid in the year0.002

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.